The Institute for Multiple Myeloma and Lymphoma
Decades of Industry Collaboration
Collaborative Framework
The landscape of partnerships in biomedical research and development is rapidly evolving. The Institute for Multiple Myeloma and Lymphoma, supported by a major philanthropic investment in 2017 by a long-time pharmaceutical partner, will be a combination of a large institute, academic drug discovery center, and risk-sharing model, funded through philanthropic investment and future commercialization initiatives. Our decades-long industry collaboration, strengthened by the transformational gift last year, will benefit patients and their families, scientists, physicians, and shareholders, while also spurring economic development in northern New Jersey – all stemming from the joint commitment to cure multiple myeloma. The institute for Multiple Myeloma and Lymphoma will hasten the development of breakthrough ideas to their full expression in clinical trials and approved interventions, ultimately offering life-saving care for patients.
Our Director:
David Siegel, M.D., Ph.D.
Rena Feinman, Ph.D.
Discovery of prognostic microbiota-associated biomarkers and development of personalized microbial-based immunotherapies for cancer patients.
In partnership with major developers of drug therapies for myeloma, Dr. Siegel and his team have brought breakthrough treatments to their patients for decades.
Discovering the cure
For decades, the study of the complex biology of multiple myeloma has consumed scientists and physicians in the field. The cure for multiple myeloma – and ultimately many other cancers – will be discovered through a multipronged and sequential approach.
The Institute for Multiple Myeloma
Faculty
Jason Butler, Ph.D.
Exploring the mechanisms by which vascular endothelial cells promote hematopoietic stem cell emergence, maintenance, and regeneration to develop therapeutic modalities to repair injured and aged hematopoietic systems.
Benjamin Tycko, M.D., Ph.D.
Genomics and epigenomics of human development and disease and its application to cancer, as well as autoimmune diseases, neurological disorders, and Down syndrome.
Johannes Zakrzewski, M.D.
Cell engineering, immuno-bioengineering and drug development based on purposeful manipulation of T cell development and NF-kB activity for targeted cancer therapy.
